Stock Research for AKRX

AKRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AKRX Stock Chart & Research Data

The AKRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AKRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AKRX Due diligence Resources & Stock Charts

The AKRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AKRX Detailed Price Forecast - CNN Money CNN View AKRX Detailed Summary - Google Finance
Yahoo View AKRX Detailed Summary - Yahoo! Finance Zacks View AKRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AKRX Trends & Analysis - Trade-Ideas Barrons View AKRX Major Holders - Barrons
NASDAQ View AKRX Call Transcripts - NASDAQ Seeking View AKRX Breaking News & Analysis - Seeking Alpha
Spotlight View AKRX Annual Report - CompanySpotlight.com OTC Report View AKRX OTC Short Report - OTCShortReport.com
TradeKing View AKRX Fundamentals - TradeKing Charts View AKRX SEC Filings - Bar Chart
WSJ View Historical Prices for AKRX - The WSJ Morningstar View Performance/Total Return for AKRX - Morningstar
MarketWatch View the Analyst Estimates for AKRX - MarketWatch CNBC View the Earnings History for AKRX - CNBC
StockMarketWatch View the AKRX Earnings - StockMarketWatch MacroAxis View AKRX Buy or Sell Recommendations - MacroAxis
Bullish View the AKRX Bullish Patterns - American Bulls Short Pains View AKRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AKRX Stock Mentions - StockTwits PennyStocks View AKRX Stock Mentions - PennyStockTweets
Twitter View AKRX Stock Mentions - Twitter Invest Hub View AKRX Investment Forum News - Investor Hub
Yahoo View AKRX Stock Mentions - Yahoo! Message Board Seeking Alpha View AKRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AKRX - SECform4.com Insider Cow View Insider Transactions for AKRX - Insider Cow
CNBC View AKRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AKRX - OTC Markets
Yahoo View Insider Transactions for AKRX - Yahoo! Finance NASDAQ View Institutional Holdings for AKRX - NASDAQ


Stock Charts

FinViz View AKRX Stock Insight & Charts - FinViz.com StockCharts View AKRX Investment Charts - StockCharts.com
BarChart View AKRX Stock Overview & Charts - BarChart Trading View View AKRX User Generated Charts - Trading View




Latest Financial News for AKRX


3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Posted on Friday April 19, 2019

LOS ANGELES, CA / ACCESSWIRE / April 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (''Akorn'' or ''the ...


Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI
Posted on Friday April 19, 2019

BOSTON, April 19, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important.


Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
Posted on Thursday April 18, 2019

Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate Ophthalmic Suspension, 0.5%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.


Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
Posted on Thursday April 18, 2019

Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.